Alembic gets tentative nod from FDA for generic Kisqali

Alembic shared that it has received tentative approval from the Food and Drug Administration for Ribociclib, 200 mg, which is the generic of Novartis’ Kisqali.

[Read more: Alembic intros generic Perforomist]

Ribociclib tablets are indicated for the treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy.